Table 1 Baseline characteristics of the patients selected from the original 3 arms
From: No radiographic wrist damage after treatment to target in recent-onset juvenile idiopathic arthritis
|  | Arm 1 Sequential monotherapy (n = 21/31) | Arm 2 Combo MTX + 6wks Prednisone (n = 18/32) | Arm 3 Combo MTX + etanercept (n = 21/29) | P |
|---|---|---|---|---|
Age (years), median (IQR) | 8.2 (4.1;10.2) | 7.9 (5.7;11.7) | 6.2 (3.8;10.4) | < 0.001 |
Symptom duration (months), median (IQR) | 7.8 (4.2;11.3) | 5.3 (2.6;6.1) | 8.5 (4.2;12.1) | 0.015 |
ANA pos, n (%) | 8 (38) | 6 (33) | 8 (28) | 0.94 |
Female, n (%) | 14 (66.7) | 9 (50) | 15 (71.4) | 0.36 |
JIA Category: | Â | Â | Â | 0.90 |
Oligo, n (%) | 3 (14.3) | 2 (11.1) | 2 (9.5) | Â |
Poly, n (%) | 17 (81) | 14 (77.8) | 18 (85.7) | Â |
Psoriatic, n (%) | 1 (4.8) | 1 (5.6) | 1 (4.8) | Â |
VAS physician, mean ± SD (mm) | 43.6 ± 15.7 | 54.0 ± 17.0 | 52.9 ± 17.5 | 0.44 |
VAS patient/parent, mean ± SD (mm) | 53 ± 17.1 | 56.8 ± 23.4 | 55.2 ± 24.9 | 0.31 |
CHAQ, mean ± SD | 0.95 ± 0.7 | 1.1 ± 0.6 | 1.0 ± 0.6 | 0.88 |
No. active joints, median (IQR) | 6 (4.5;14.5) | 8 (5.8;11.5) | 8 (5.5;11.5) | 0.56 |
No. limited joints, median (IQR) | 2 (0.5;4) | 1.5 (0.8;3.3) | 3 (2.5;5.5) | 0.68 |
ESR, median (IQR) (mm) | 6 (2;12) | 6 (3.5;32) | 9 (6;31.5) | 0.28 |
JADAS-10 mean ± SD (0–40) | 16.7 ± 4.5 | 19.6 ± 5.1 | 19.1 ± 5.8 | 0.24 |
Z-score Poznanski median (IQR)1 | −0.45 (− 0.70;0.56) | −0.19 (− 0.57;0.68) | −0.61 (− 0.82;0.17) | 0.056 |
Z-score Bone Age mean (CI)2 | −0.38 (− 0.88;0.11) | 0.51 (0.28;0.74) | −0.43 (− 0.82;−0.04) | 0.001 |
Z-score BMD mean (CI)3 | −0.44 (− 0.84;−0.04) | −0.39 (− 0.93;0.15) | −1.08 (− 1.48;−0.68) | 0.03 |
Wrist arthritis, inclusion (%) | 19/21 (90) | 14/18 (78) | 18/21 (86) | Â |
Wrist arthritis, follow-up (%) | 17/21 (81) | 14/18 (78) | 18/21 (86) | Â |
Wrist arthritis, inclusion or follow-up (%) | 21/21 (100) | 14/18 (78) | 19/21 (90) | Â |